CRISTEL Study: Monitoring of Pregnancies in Women After Solid Organ Transplantation (CRISTEL)
研究概览
详细说明
According to North American and Australian registries, pregnancy is both a joyful and high-risk event for women who have received a solid organ transplant. Typically, a transplanted woman has a probability comparable to that of the general population of giving birth to a live infant, but she is likely to deliver prematurely (median gestational age: 32 weeks), to have a growth-restricted baby (median birth weight around 2.3 kg), and often in a context of preeclampsia (in at least 30% of cases)(1).
Today, these are the data shared with patients planning a pregnancy, despite uncertainty as to their accuracy and applicability in France or even Europe.
Among the unknowns that remain despite these registry data, the following should be noted:
Uncertainty about the level of pregnancy planning in this specific context: What proportion of women of childbearing age have been informed of the possibility of becoming pregnant, of the associated risks, and of necessary precautions (e.g., stopping mycophenolate mofetil at least 6 weeks before conception);
Variability in the information provided from one center to another, due to the absence of a national, consensus-based document addressing fertility and contraception in the post-transplantation setting;
Monitoring frequency specific to the graft, especially regarding exposure to immunosuppressive drugs (and consequently actual exposure to calcineurin inhibitors, the cornerstone of anti-rejection therapy, whose residual blood concentration varies from the second trimester onward)(2);
The true risk of preeclampsia, at a time when diagnosis can be refined by measuring levels of placental-derived anti-angiogenic factors in maternal serum (sFlt-1/PlGF ratio)(3), and by uterine artery Doppler;
The incidence of de novo anti-HLA immunization (HLA antigens expressed by the fetus and inherited from the father), which can now be assessed using the Luminex technique(4);
Maternal morbidity: What is the impact of pregnancy on graft function? Conversely, how does renal function influence pregnancy outcomes, regardless of the transplanted organ?
Infant morbidity in the short and medium term.
To establish these data and to provide accurate information to patients, we aim to conduct a study among pregnant women who have undergone solid organ transplantation (kidney, heart, lung, liver, or pancreas). The objective of this research is to collect standardized and independent data on the number of pregnancies occurring in France and to monitor them up to one year postpartum (or after pregnancy termination).
The study will then aim to describe the clinical characteristics and maternal and perinatal outcomes of pregnancies in this specific population. These data will help disseminate clear and up-to-date information to the medical community, thus improving patient counseling and, more broadly, support for couples. They will also serve to develop recommendations to optimize the planning and management of pregnancies in women with solid organ transplants.
Finally, this initiative aims to promote clinical research on pregnancy in the context of transplantation, particularly through clinical trials and the development of biobanks.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Sahar Pr SELLAMI JALLOULI, PhD
- 电话号码:01 46 25 31 37
- 邮箱:s.sellami-jallouli@hopital-foch.com
参与标准
资格标准
适合学习的年龄
- 成人
接受健康志愿者
描述
Inclusion Criteria:
- Female patient aged 18 years or older and of childbearing age
- Has received a solid organ transplant, either isolated or combined (heart, liver, lung, pancreas, kidney)
- Has a positive blood beta-hCG test result > 5 IU/L ("positive")
- Has signed an informed consent form
- Affiliated with a health insurance plan
Exclusion Criteria:
- Patient deprived of liberty or under legal guardianship
- Patient refuses to participate in the study
学习计划
研究是如何设计的?
设计细节
- 主要用途:放映
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
其他:Adult female patients who have received a solid organ transplant
Adult female patients who have received a solid organ transplant, either isolated or combined (heart, liver, lung, pancreas, kidney), and who present with a positive beta-hCG blood test result (defined by a threshold of 5 IU/L) in one of the participating centers, or who are planning a pregnancy, will initially be identified.
|
Two optional (non-mandatory) biological samples may be collected as part of this study: A 2 mL venous blood sample may be taken during a routine prenatal follow-up visit (around 30 weeks of gestation) in order to analyze the preeclampsia biomarker (sFlt-1/PlGF ratio), whenever preeclampsia is suspected. A 5 mL sample from cord blood may be collected after delivery to analyze, in the newborn, the complete blood count, white blood cell differential, lymphocyte phenotyping (T CD3+, CD19+CD20+, and NK CD46+), and immunoglobulin levels (G, A, and M for humoral immunity, and E for allergy-related function). |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
The primary outcome is the annual incidence of conception in the population of women with solid organ transplants (i.e., included in the study).
大体时间:Annually over the 10-year study period
|
The primary outcome is the annual incidence of conception in the population of women with solid organ transplants (i.e., included in the study).
|
Annually over the 10-year study period
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Rate of preeclampsia
大体时间:Through study completion, an average of 1 year
|
Rate of preeclampsia
|
Through study completion, an average of 1 year
|
|
Trajectory of estimated glomerular filtration rate (eGFR, in mL/min/1.73 m²);
大体时间:3 months and 12 months postopartum
|
Trajectory of estimated glomerular filtration rate (eGFR, in mL/min/1.73
m²);
|
3 months and 12 months postopartum
|
|
Live birth rate among transplanted mothers from the onset of pregnancy.
大体时间:through study completion, an average of 1 year
|
Live birth rate among transplanted mothers from the onset of pregnancy.
|
through study completion, an average of 1 year
|
|
Trajectory of serum creatinine levels
大体时间:During pregnancy (up to 40 weeks if gestation)
|
Trajectory of serum creatinine levels
|
During pregnancy (up to 40 weeks if gestation)
|
|
Rate of maternal complications before delivery and in the postpartum period (infectious episodes, rejection episodes, therapeutic pregnancy termination, postpartum hemorrhage)
大体时间:During pregnancy (up to 40 weeks of gestation) and during post partum from delivery up to about 1 year after birth
|
Rate of maternal complications before delivery and in the postpartum period (infectious episodes, rejection episodes, therapeutic pregnancy termination, postpartum hemorrhage)
|
During pregnancy (up to 40 weeks of gestation) and during post partum from delivery up to about 1 year after birth
|
|
Mode of delivery (spontaneous labor, induced labor, planned cesarean section, or emergency cesarean section); gestational age at delivery (in weeks of gestation); proportion of gestational hypertension and preeclampsia.
大体时间:Day of delivery: Perioperative/Periprocedural
|
Mode of delivery (spontaneous labor, induced labor, planned cesarean section, or emergency cesarean section); gestational age at delivery (in weeks of gestation); proportion of gestational hypertension and preeclampsia.
|
Day of delivery: Perioperative/Periprocedural
|
|
Birth weight of the newborn (in grams)
大体时间:day of delivery
|
Birth weight of the newborn (in grams)
|
day of delivery
|
|
Rate of spontaneous miscarriage
大体时间:Through study completion, an average of 1 year
|
Rate of spontaneous miscarriage
|
Through study completion, an average of 1 year
|
|
Rate of cesarean section
大体时间:Through study completion, an average of 1 year
|
Rate of cesarean section
|
Through study completion, an average of 1 year
|
|
Rate of prematurity
大体时间:Through study completion, an average of 1 year
|
Rate of prematurity
|
Through study completion, an average of 1 year
|
|
Rate of intrauterine growth restriction
大体时间:Through study completion, an average of 1 year
|
Rate of intrauterine growth restriction
|
Through study completion, an average of 1 year
|
|
the duration of hospital stay for both the mother and the newborn
大体时间:Through study completion, an average of 1 year
|
the duration of hospital stay for both the mother and the newborn
|
Through study completion, an average of 1 year
|
|
incidence of biopsy-proven acute rejection up to 12 months postpartum;
大体时间:up to 12 months postpartum;
|
incidence of biopsy-proven acute rejection up to 12 months postpartum;
|
up to 12 months postpartum;
|
|
incidence of de novo anti-HLA sensitization at 3 and 12 months postpartum.
大体时间:3 months and 12 months postoartum
|
incidence of de novo anti-HLA sensitization at 3 and 12 months postpartum.
|
3 months and 12 months postoartum
|
|
Trajectory of proteinuria (protein-to-creatinine ratio)
大体时间:During pregnancy (up to 40 weeks if gestation)
|
Trajectory of proteinuria (protein-to-creatinine ratio)
|
During pregnancy (up to 40 weeks if gestation)
|
|
Trajectory of tacrolimus blood levels, and anti-angiogenic factors during pregnancy,
大体时间:During pregnancy (up to 40 weeks if gestation)
|
Trajectory of tacrolimus blood levels, and anti-angiogenic factors during pregnancy,
|
During pregnancy (up to 40 weeks if gestation)
|
|
Trajectory of anti-angiogenic factors during pregnancy
大体时间:During pregnancy (up to 40 weeks if gestation)
|
Trajectory of anti-angiogenic factors during pregnancy
|
During pregnancy (up to 40 weeks if gestation)
|
|
Rate of maternal complications and hospitalizations before delivery and in the postpartum period (infectious episodes, rejection episodes, therapeutic pregnancy termination, postpartum hemorrhage)
大体时间:During pregnancy (up to 40 weeks of gestation) and during post partum from delivery up to about 1 year after birth
|
Rate of maternal hospitalizations before delivery and in the postpartum period
|
During pregnancy (up to 40 weeks of gestation) and during post partum from delivery up to about 1 year after birth
|
|
Apgar score
大体时间:day of delivery
|
Apgar score
|
day of delivery
|
|
Proportion of growth-restricted
大体时间:day of delivery and up 3 month postpartum
|
Proportion of growth-restricted
|
day of delivery and up 3 month postpartum
|
|
Incidence of neonatal complications before the third month of life
大体时间:day of delivery and up 3 month postpartum
|
Incidence of neonatal complications before the third month of life
|
day of delivery and up 3 month postpartum
|
合作者和调查者
赞助
调查人员
- 首席研究员:Alexandre Pr Hertig, MED、Foch Hospital
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.